Emcure Pharmaceuticals

Audio recording of Earnings Call - Q3 FY26

04 Feb, 2026 | 06:35pm • Source: BSE

Disclosure under Regulation 30(5) of the SEBI Listing Regulations intimating about authorising Key Managerial Personnel of the Company for the purpose of determining the materiality...

04 Feb, 2026 | 03:07pm • Source: BSE

Re-appointment of Independent Directors of the Company.

04 Feb, 2026 | 02:29pm • Source: BSE

Appointment of Ms. Amruta Jana Yangalwar as Company Secretary and Compliance Officer of the Company.

04 Feb, 2026 | 02:08pm • Source: BSE

Unaudited Financial Results (Consolidated and Standalone) for the quarter and nine months ended December 31, 2025

04 Feb, 2026 | 01:40pm • Source: BSE

Outcome of Board Meeting held on February 04, 2026.

04 Feb, 2026 | 01:32pm • Source: BSE

Intimation for Earnings Call - Q3 FY26

22 Jan, 2026 | 04:19pm • Source: BSE

Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 ,inter alia, to consider and...

22 Jan, 2026 | 04:05pm • Source: BSE

Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018, for the quarter ended December 31, 2025.

07 Jan, 2026 | 01:24pm • Source: BSE

Press Release titled "Emcure expands Weight Management Therapy access with launch of Poviztra".

22 Dec, 2025 | 11:40am • Source: BSE

Intimation of schedule of Analyst/ Investor Meeting(s)

01 Dec, 2025 | 09:13pm • Source: BSE

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding search and seizure/ inspection operation conducted by Good & Service...

27 Nov, 2025 | 04:38pm • Source: BSE

Mr. Chetan Sharma (FCS:8352) has submitted his resignation from post of company Secretary and Compliance Officer & Key Managerial Personnel of the Company, with effect...

21 Nov, 2025 | 05:57pm • Source: BSE

Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation

19 Nov, 2025 | 12:29pm • Source: NSE

Investor Presentation for Investor Conferences, to be attended by officials of the Company, on November 19, 2025 and November 20, 2025

19 Nov, 2025 | 11:07am • Source: BSE

Transcript of Earnings Call - Q2 FY26

17 Nov, 2025 | 04:36pm • Source: BSE

Intimation of schedule of Analyst/ Investor Meeting(s)

14 Nov, 2025 | 06:24pm • Source: BSE

Intimation of schedule of Analyst/ Investor Meeting(s)

14 Nov, 2025 | 06:21pm • Source: BSE

Audio recording of Earnings Call - Q2 FY26

11 Nov, 2025 | 05:06pm • Source: BSE

Unaudited Financial Results (Consolidated and Standalone) for the quarter and half-year ended September 30, 2025

11 Nov, 2025 | 01:39pm • Source: BSE